Riskpilot← Back to searchSign inGet full accessSpeculum AB
ABActiveOrg 5592870447Rademachergatan 19 Specialist MottagningMedical specialists activities · NACE 8622Est. 20202 employees
Revenue 2024
SEK 4,1M
+4% vs 2023
EBITDA margin
35.5%
+3% vs 2023
Equity ratio
56.0%
Financial strength
Net profit 2024
SEK 981K
+123% vs 2023
| Revenue | SEK 4,1M | +4% |
| EBITDA | SEK 1,5M | +3% |
| Net profit | SEK 981K | +123% |
| Total assets | SEK 2,4M | +102% |
| Equity | SEK 1,4M | +115% |
| Employees | 2 | — |
Legal name
Speculum AB
Org number
5592870447
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
2 december 2020
Share capital
SEK 25 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva läkarmottagning och annan därmed förenlig medicinsk verksamhet.
Address
Rademachergatan 19 Specialist Mottagning
Email
ali.kanaan777@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 3 437 | 3 589 | 3 951 | 4 092 |
| Staff expenses | — | — | — | −1 802 |
| EBITDA | 1 270 | 1 305 | 1 413 | 1 453 |
| Depreciation & amort. | −22 | −55 | −104 | −130 |
| EBIT | 1 248 | 1 250 | 1 309 | 1 323 |
| Net financials | −1 | −8 | −3 | −35 |
| Profit before tax | 997 | 743 | 555 | 1 238 |
| Tax | −214 | −154 | −116 | −258 |
| Net profit | 783 | 589 | 439 | 981 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 1 521 | 1 584 | 1 210 | 2 438 |
| Equity | 808 | 696 | 635 | 1 366 |
| Long-term debt | 0 | 0 | 0 | 38 |
| Short-term debt | 463 | 638 | 325 | 785 |
| Total debt | 463 | 638 | 325 | 822 |
EBITDA margin
35.5%
This company
15.8%
Market median
+125% vs market
20212024
Equity ratio
56.0%
This company
38.2%
Market median
+47% vs market
20212024
Return on equity
71.8%
This company
18.4%
Market median
+290% vs market
20212024
Net profit margin
24.0%
This company
8.1%
Market median
+196% vs market
20212024
Asset turnover
1.68×
This company
1.12×
Market median
+50% vs market
20212024
Debt / equity
0.79×
This company
0.62×
Market median
+27% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-12-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RK Audit | Audit | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2024 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ysn Läkarkonsult AB | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ysn Läkarkonsult AB
Speculum AB Board members of Speculum AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rimon Khames | Audit | 0 companies |
| Shimaa Seifeddin Ezzidin | Deputy Board Member | 0 companies |
| Mohammad Seifeddin Ezzidin | Deputy Board Member | 0 companies |
| Ali Hussain Rijab Kanaan | Board of Directors | 0 companies |
| Ann-Britt Elisabet Henriksson | Deputy Board Member | 0 companies |
| Saheb Ejbari Safi | Deputy Board Member | 0 companies |
| Staffan Olof Henriksson | Board of Directors | 0 companies |